EUROPEAN CURRICULUM VITAE FORMAT

PERSONAL INFORMATION

Name	**MAURIZIO SCARPA**
Address	Regional Coordinating Centre for Rare Disease – University Hospital "Santa Maria della Misericordia" – Piazzale Santa Maria della Misericordia, 15 – 33100 Udine (Italy)
Telephone	+39 0432 559883 Mobile +39 3480 33390
Fax	
E-mail	**maurizio.scarpa@asufc.sanita.fvg.it**
Nationality	Italian
Date of birth and place	SEPTEMBER 15, 1959, VENICE ITALY

WORK EXPERIENCE

MAIN ACTIVITIES AND RESPONSIBILITIES

Coordinator, MetabERN European Reference Network for Hereditary Metabolic Diseases, Past-Chair ERN Coordinators Group.

Associate Professor of Pediatrics; University of Padova, Italy,
National Abilitation to Full Professor of Pediatrics 03-2017.
H INDEX: 34

1991- 2014: Head Lysosomal Unit, Dept. of Pediatrics University of Padova,

1995-1997: Staff Pediatric Intensive Care Unit, Dept. of Pediatrics University of Padova,

1997- 2016: Consultant in General Pediatrics . Laguna Medical Centre Venice, Italy

1997-2005; Staff, Inherited Metabolic Diseases Unit, Dept.of Pediatrics, Padova

2005-2014: Staff, Pediatric Neurology Unit Dept. Of Pediatrics Padova,

2011- 2015: Director, Centre for Rare Disease IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Research Hospital

2014-2018: Director Center for Rare Diseases, Horst Schmidt Klinik, Wiesbaden. DE

2017- present: Coordinator European Reference Network for Hereditary Metabolic Diseases: MetabERN and Past-Chair ERN Coordinators Group

2019-present: Director, Regional Coordinating Center for Rare Diseases, Udine University Hospital, Udine, Italy

2019-present: Scientific Director UDINE University Hospital, Udine, Italy

EDUCATION AND TRAINING	1980-1985: Working group on Cystic Fibrosis, Dept. of Pediatrics, University of Padova, Italy. 1985: M.D. DEGREE, UNIVERSITY OF PADOVA, Medical School , Padova, Italy. 1985-1987: MOLECULAR BIOLOGY TRAINING: Postdoctoral fellowship for Prof. Gianni Cesareni's laboratory, Dept. Gene Structure and Regulation European Molecular Biology Laboratory, (E.M.B.L.) Heidelberg, Germany; 1988-1990: MOLECULAR GENETICS AND CLINICAL GENETICS TRAINING: Postdoctoral Fellowship. Prof. Charles Thomas Caskey's laboratory. Institute for Molecular Genetics, Baylor College of Medicine, Houston,Texas, U.S.A. 1989: SPECIALIST ON PEDIATRICS, UNIVERSITY OF PADOVA 1990-1993: CONSULTANT IN MOLECULAR BIOLOGY Prof. GianFranco Bottazzo's Laboratory, Department of Immunology, The London Hospital Medical College, London, UK. 2004: PHD DEGREE: PEDIATRIC SCIENCES 15/Jan/1986: Medical Registry Number :4331
CERTIFICATIONS	1985: Medical Doctor Degree, University of Padova, Italy. 1985: License for Medical Practice, Italian Ministry of Health 1989: Diploma of Pediatrics, Department of Pediatrics, University of Padova, Italy. 2004: PhD Degree, Pediatric Sciences, University of Padova, Medical School 16 Jul 2019: ICH GOOD CLINICAL PRACTICE E6(R2)
ACADEMICAL TEACHING ACTIVITIES	2004-2011: Director PhD Programme on Molecular Genetics and Biochemistry, University of Padova, I 2004-2010: Professor of Applied Biology, School of Neurosurgery, University of Padova 2004-2010: Professor of Biochemistry, School of Neuropsichiatry University of Padova 2004-2010: Professor of Molecular Biology School of Neuropsichiatry University of Padova. 2014-present: Professor of Pediatrics, School of Medicine , University of

Padova, Italy

MEMBERSHIP

1990-pres: Member of the Italian Society of Pediatrics

1992: Founding Member of the European Society for Gene Therapy

1994- pres.: Member of the Scientific Committee,
Italian Association for Mucopolysaccharidosis.

1994-1996 Member of the Gene Therapy Committee Italian Minister for the EEC, Commission on Safety of Genetically Modified Microorganisms.

1999-pres.: Member of the European Study Group for Lysosomal Diseases (ESLGD)

2000- pres. Society for the Study of the Inborn Errors of Metabolism (SSIEM)

2007: Founder of BRAINS FOR BRAIN European Task Force for the Research on Pediatric Neurodegenerative Disorders

2008- present: Board Member of the European Brain Council

2009-2011: VicePresident, BRAINS For BRAIN FOUNDATION

2012-2017: President BRAINS For BRAIN FOUNDATION

2017: Present, Member Scientific Committee for Therapy Development, IRDIRC International Rare Diseases Research Consortium

REVIEWER ACTIVITY

Reviewer for the EU Community FP7 Programme
Member of the Expert panel of the European Science Foundation
Reviewer for the Medical Research Council, UK
Reviewer for the French Research Council
Reviewer for the Cochraine Clinical Trial Organization
Gene Review expert

International Journals:
Gene Therapy, Human Gene Therapy, Clinical Chemistry, Pediatrics, J. Pediatrics, Nanomedicine. Orphanet Journal of Rare Diseases, Molecular Genetics and Metabolism, American Journal Human Gentics,

Communicating Editor: Journal Inherited Metabolic Diseases

CONFLICT OF INTERESTS GRANTS FOR RESEARCH, UNRESTRICTED EDUCATIONAL ACITIVITES ADVISORY BOARD HONORARIA FROM: ACTELION, ALEXION, BIOMARIN, BIOASIS, CHIESI, GENZYME SANOFY, SHIRE, PTC THERAPEUTICS, VTESSE

PUBLICATIONS

1. Antagonistic controls regulate copy number of the yeast 2 mu plasmid..
   MURRAY, JA;SCARPA, M;ROSSI, N;CESARENI, G.
   EMBO J. 1988. ; 6:4205-12

2. Genetic and structural analysis of the ColE1 Rop (Rom) protein..
   CASTAGNOLI, L;SCARPA, M;KOKKINIDIS, M;BANNER, DW;TSERNOGLOU, D;CESARENI, G.
   EMBO J. 1989. ; 8:621-9

3. Determination of base specificity in 6,4,4'-trimethylangelicin photobinding to single-stranded DNA..
   MIOLO, G;SCARPA, M;DALL'ACQUA, F;ZACCHELLO, F.
   J PHOTOCH PHOTOBIO B. 1989. ; 3:123-7

4. Gene therapy: a new approach for the treatment of genetic disorders..
   COURNOYER, D;SCARPA, M;JONES, SN;MOORE, KA;BELMONT, JW;CASKEY, CT.
   Clinical Pharmacology and Therapeutics. 1990. ; 47:1-11

5. SCREENING FOR CYSTIC-FIBROSIS GENE-MUTATIONS BY MULTIPLEX DNA AMPLIFICATION.
   PICCI, L; ANGLANI, F; SCARPA, M; ZACCHELLO, F.
   HUM GENET. 1992. ; 88(5):552-556

6. Screening for cystic fibrosis gene mutations by multiplex DNA amplification..
   PICCI, L;ANGLANI, F;SCARPA, M;ZACCHELLO, F .
   HUM GENET. 1992. ; 88:552-6

7. Gene therapy..
   COURNOYER, D;SCARPA, M;CASKEY, CT.
   Current Opinion in Biotechnology. 1992. ; 1:196-208

8. Evaluation of lymphoid-specific enhancer addition or substitution in a basic retrovirus vector..
   MOORE, KA;SCARPA, M;KOOYER, S;UTTER, A;CASKEY, CT;BELMONT, JW.
   Human gene therapy. 1992. ; 2:307-15

9. Gene transfer of adenosine deaminase into primitive human hematopoietic progenitor cells..
   COURNOYER, D;SCARPA, M;MITANI, K;MOORE, KA;MARKOWITZ, D;BANK, A;BELMONT, JW;CASKEY, CT.
   Human gene therapy. 1992. ; 2:203-13

10. GENE-TRANSFER IN REGENERATING MUSCLE.
VITADELLO, M; NOVELLI, A; PICARD, A; SCHIAFFINO, MV; SCARPA, M; SCHIAFFINO, S.
J CELL BIOCHEM. 1993. ; 0(0):252

11. GENE-TRANSFER IN REGENERATING MUSCLE.
VITADELLO, M; SCHIAFFINO, MV; PICARD, A; SCARPA, M; SCHIAFFINO, S.
Human gene therapy. 1994. ; 5(1):11-18

12. ANTIRETROVIRAL ACTIVITY OF FUROCOUMARINS PLUS UVA LIGHT DETECTED BY A REPLICATION-DEFECTIVE RETROVIRUS.
MIOLO, G; TOMANIN, R; DEROSSI, A; DALLACQUA, F; ZACCHELLO, F; SCARPA, M.
J PHOTOCH PHOTOBIO B. 1994. ; 26(3):241-247

13. Gene transfer in regenerating muscle..
VITADELLO, M;SCHIAFFINO, MV;PICARD, A;SCARPA, M;SCHIAFFINO, S.
Human gene therapy. 1994. ; 5:11-8

14. Antiretroviral activity of furocoumarins plus UVA light detected by a replication-defective retrovirus..
MIOLO, G;TOMANIN, R;DE, ROSSI, A;DALL'ACQUA, F;ZACCHELLO, F;SCARPA, M.
J PHOTOCH PHOTOBIO B. 1995. ; 26:241-7 IF:

15. In vitro and in vivo gene transfer to pulmonary cells mediated by cationic liposomes.
Fortunati, E; Bout, A; Zanta, MA; Valerio, D; Scarpa, M.
BBA-GENE STRUCT EXPR. 1996. ; 1306(1):55-62

16. ExGen 500 is an efficient vector for gene delivery to lung epithelial cells in vitro and in vivo.
Ferrari, S; Moro, E; Pettenazzo, A; Behr, JP; Zacchello, F; Scarpa, M.
GENE THER. 1997. ; 4(10):1100-1106

17. The bacteriophage T7 binary system activates transient transgene expression in zebrafish (Danio rerio) embryos.
Verri, T; Argenton, F; Tomanin, R; Scarpa, M; Storelli, C; Costa, R; Colombo, L; Bortolussi, M.
BIOCHEM BIOPH RES CO. 1997. ; 237(3):492-495

18. Development and characterization of a binary gene expression system based on bacteriophage T7 components in adenovirus vectors.
Tomanin, R; Bett, AJ; Picci, L; Scarpa, M; Graham, FL.
GENE. 1997. ; 193(2):129-140

19. In vitro correction of iduronate-2-sulfatase deficiency by adenovirus-mediated gene transfer.
DiFrancesco, C; Cracco, C; Tomanin, R; Picci, L; Ventura, L; Zacchello, F; DiNatale, P; Anson, DS; Hopwood, JJ; Graham, FL; Scarpa, M.
GENE THER. 1997. ; 4(5):442-448

20. In vitro and in vivo antitumor effects of retrovirus-mediated herpes simplex thymidine kinase gene-transfer in humar medulloblastoma.
Rosolen, A; Frascella, E; di Francesco, C; Todesco, A; Petrone, M; Mehtali, M; Zacchello, F; Zanesco, L; Scarpa, M.
GENE THER. 1998. ; 5(1):113-120

21. ExGen 500 is an efficient vector for gene delivery to lung epithelial cells in vitro and in vivo..
FERRARI, S;MORO, E;PETTENAZZO, A;BEHR, JP;ZACCHELLO, F;SCARPA, M.
GENE THER. 1998. ; 4:1100-6

22. Polyethylenimine shows properties of interest for cystic fibrosis gene therapy.
Ferrari, S; Pettenazzo, A; Garbati, N; Zacchello, F; Behr, JP; Scarpa, M.
BBA-GENE STRUCT EXPR. 1999. ; 1447(2):219-225

23. Recombinant adenoviral vector-LipofectAMINE complex for gene transduction into human T lymphocytes.
Di Nicola, M; Milanesi, M; Magni, M; Bregni, M; Carlo-Stella, C; Longoni, P; Tomanin, R; Ravagnani, F; Scarpa, M; Jordan, C; Gianni, AM.
Human gene therapy. 1999. ; 10(11):1875-1884

24. Detection of five rare cystic fibrosis mutations peculiar to southern Italy: Implications in screening for the disease and phenotype characterization for patients with homozygote mutations.
Castaldo, G; Fuccio, A; Cazeneuve, C; Picci, L; Salvatore, D; Raia, V; Scarpa, M; Goossens, M; Salvatore, F.
CLIN CHEM. 1999. ; 45(7):957-962

25. A noval nonsense mutation (Y849X) in the CFTR gene of a CF patient from southern Italy..
Castaldo, G;Fuccio, A;Cazeneuve, C;Picci, L;Salvatore, D;Scarpa, M;Goossens, M;Salvatore, F. .
HUM MUTAT. 1999. ; 14:-

26. Large-scale feasibility of gene transduction into human CD34(+) cell-derived dendritic cells by adenoviral/polycatior complex.
Di Nicola, M; Carlo-Stella, C; Milanesi, M; Magni, M; Longoni, P; Mortarini, R; Anichini, A; Tomanin, R; Scarpa, M; Gianni, AM.
BRIT J HAEMATOL. 2000. ; 111(1):344-350

27. Mucus altering agents as adjuncts for nonviral gene transfer to airway epithelium.
Ferrari, S; Kitson, C; Farley, R; Steel, R; Marriott, C; Parkins, DA; Scarpa, M; Wainwright, B; Evans, MJ; Colledge, WH; Geddes, DM; Alton, EWFW.
GENE THER. 2001. ; 8(18):1380-1386

28. Update on enzyme replacement therapy in mucopolysaccharidosis type II.
Muenzer, J; Scarpa, M.
ACTA PAEDIATR. 2002. ; 91(0):81

29. Non-viral transfer approaches for the gene therapy of mucopolysaccharidosis type II (Hunter syndrome).
Tomanin, R; Friso, A; Alba, S; Puicher, EP; Mennuni, C; La Monica, N; Hortelano, G; Zacchello, F; Scarpa, M.
ACTA PAEDIATR. 2002. ; 91(0):100-104

30. Uptake of recombinant iduronate-2-sulfatase into neuronal and glial cells in vitro.
Daniele, A; Tomanin, R; Villani, GRD; Zacchello, F; Scarpa, M; Di Natale, P.
Biochimica et Biophysica Acta - Molecular Basis of Disease. 2002. ; 1588(3):203-209

31. Electrogene transfer in Mucopolysaccharidosis type II mouse model induces high-level production of iduronate-2-sulfatase in the skeletal muscle.
Tomanin, R; Friso, A; Alba, S; Puicher, EP; Gasparotto, N; Mennuni, C; La Monica, N; Muenzer, J; Zacchelio, F; Scarpa, M.
MOL THER. 2003. ; 7(5):1024 -

32. Non-viral transfer approaches for the gene therapy of mucopolysaccharidosis type II (Hunter syndrome)..
TOMANIN, R;FRISO, A;ALBA, S;PILLER, PUICHER, E;MENNUNI, C;LA, MONICA, N;HORTELANO, G;ZACCHELLO, F;SCARPA, M .
ACTA PAEDIATR. 2003. ; 91:100-4

33. Chimeric vectors.
Scarpa, M.
Current gene therapy. 2004. ; 4(4):

34. Why do we need new gene therapy viral vectors? Characteristics, limitations and future perspectives of viral vector transduction.
Tomanin, R; Scarpa, M.
Current gene therapy. 2004. ; 4(4):357-372

35. Reduction of GAG storage in MPS II mouse model following implantation of encapsulated recombinant myoblasts.
Friso, A; Tomanin, R; Alba, S; Gasparotto, N; Puicher, EP; Fusco, M; Hortelano, G; Muenzer, J; Marin, O; Zacchello, F; Scarpa, M.
J GENE MED. 2005. ; 7(11):1482-1491

36. Gender-sensitive association of CFTR gene mutations and 5T allele emerging from a large survey on infertility.
Morea, A; Cameran, M; Rebuffi, AG; Marzenta, D; Marangon, O; Picci, L; Zacchello, F; Scarpa, M.
MOL HUM REPROD. 2005. ; 11(8):607-614

37. Update on enzyme replacement therapy (ERT) with recombinant human arylsulfatase B (rhASB) for MPS VI (Maroteaux-Lamy).
Harmatz, P; Giugliani, R; Schwartz, I; Guffon, N; Miranda, CS; Teles, E; Wraith, JE; Beck, M; Scarpa, M; Yu, ZF; Wittes, J; Berger, K; Newman, M.
PEDIATR RES. 2005. ; 58(2):169 -

38. Cystic fibrosis carriers have higher neonatal immunoreactive trypsinogen values than non-carriers.
Castellani, C; Picci, L; Scarpa, M; Dechecchi, MC; Zanolla, L; Assael, BM; Zacchello, F.
AM J MED GENET A. 2005. ; 135(2):142-144

39. A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, MULTINATIONAL CLINICAL STUDY OF RECOMBINANT HUMAN N-ACETYLGALACTOSAMINE 4 SULFATASE (RHASB) IN PATIENTS WITH MUCOPOLYSACCHARIDOSIS VI.
Guffon, N.; Harmatz, P.; Giugliani, R.; Schwartz, I.; Miranda, C.; Teles, E.; Wraith, Ed; Beck, M.; Arash, L.; Scarpa, M.; Swiedler, S..
J INHERIT METAB DIS. 2005. ; 28(0):190

40. A 3-year-old child with abdominal pain and fever..
BONETTO, G;SCARPA, M;CARRARO, S;BARALDI, E.
EUR RESPIR J. 2005. ; 26:974-7

41. Enzyme replacement therapy for mucopolysaccharidosis VI: A Phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study.
Harmatz, P; Giugliani, R; Schwariz, I; Guffon, N; Teles, EL; Miranda, MCS; Wraith, JE; Beck, M; Arash, L; Scarpa, M; Yu, ZF; Wittes, J; Berger, KI; Newman, MS; Lowe, AM; Kakkis, E; Swiedler, SJ.
J PEDIATR. 2006. ; 148(4):533-539

42. Long term benefit and safety with recombinant human arylsulfatase, B (rhASB) ERT for MPS VI.
Harmatz, P.; Giugliani, R.; Schwartz, I.; Guffon, N.; Sa Miranda, C.; Teles, E.; Wraith, J. E.; Beck, M.; Scarpa, M.; Yu, Z-F; Rhorer, J.; Swiedler, S. J.; Decker, C..
J INHERIT METAB DIS. 2006. ; 29(0):29

43. Neurological examinations and clinical manifestations in MPS I as reported in the MPS I registry.
Scarpa, M..
J INHERIT METAB DIS. 2007. ; 30(0):97

44. Phase 3 extension 96-week study data for naglazyme (galsulfase) enzyme replacement therapy (ERT) in MPS VI (Maroteaux-Lamy syndrome) patients.
Harmatz, P.; Gingliani, R.; Schwartz, I; Guffon, N.; Sa, Miranda C.; Teles, E.; Wraith, J.; Beck, M.; Scarpa, M.; Yu, Z. F.; Rhorer, J.; Swiedler, S.; Turbeville, S.; Nicely, H.; White, J.; Decker, C..
J INHERIT METAB DIS. 2007. ; 30(0):116

45. TG15 T5 allele in clinically discordant monozygotic twins with cystic fibrosis.
Picci, Luigi; Cameran, Marilena; Scarpa, Maurizio; Pradal, Ugo; Melotti, Paola; Assael, Baroukh M.; Castellani, Carlo.
AM J MED GENET A. 2007. ; 143(16):1936-1937 IF:

46. Efficiency of stem cell infections of amniotic fluid by means of adenoviral carriers.
Piccoli, M.; Grisafi, D.; Pozzobon, M.; Bollini, S.; Marangoni, P.; Carli, M.; Zanesco, L.; Scarpa, M.; De, Coppi P.; Tomanin, R..
HAEMATOL-HEMATOL J. 2007. ; 92(6):45-45

47. Neurologic examinations and clinical manifestations in mucopolysaccharidosis I: MPS I registry data.
Scarpa, M..
Clinical Therapeutics. 2007. ; 29(0):S123-S123

48. High Transduction Efficiency of Human Amniotic Fluid Stem Cells Mediated by Adenovirus Vectors.
Grisafi, Davide; Piccoli, Martina; Pozzobon, Michela; Ditadi, Andrea; Zaramella, Patrizia; Chiandetti, Lino; Zanon, Giovanni Franco; Atala, Anthony; Zacchello, Franco; Scarpa, Maurizio; De Coppi, Paolo; Tomanin, Rosella.
Stem Cells and Development. 2008. ; 17(5):953-962

49. Gene therapy of Hunter syndrome: Evaluation of the efficiency of muscle electro gene transfer for the production and release of recombinant iduronate-2-sulfatase (IDS).
Friso, A.; Tomanin, R.; Zanetti, A.; Mennuni, C.; Calvaruso, F.; La Monica, N.; Marin, O.; Zacchello, F.; Scarpa, M..
Biochimica et Biophysica Acta - Molecular Basis of Disease. 2008. ; 1782(10):574-580

50. Molecular analysis of 82 mucopolysaccharidosis type I patients: Mutational spectrum in the European population and identification of 28 novel mutations.
Bertola, F.; Parini, R.; Casati, G.; Tylki-Szymanska, A.; Okur, I; Tuysuz, B.; Dalmau, J.; Gonzales, Meneses A.; Antuzzi, D.; Barone, R.; Dionisi, Vici C.; Donati, A.; Filocamo, M.; Gabrielli, O.; Parenti, G.; Scarpa, M.; Uziel, G.; Biondi, A..
J INHERIT METAB DIS. 2008. ; 31(0):426P -

51. Morquio syndrome: Gene expression profiling and elastic fiber assembly in patients' fibroblasts.
Caciotti, A.; Carraresi, L.; Filoni, C.; Parini, R.; Antuzzi, D.; Ricci, R.; Scarpa, M.; Procopio, E.; Dazzo, A.; Zammarchi, E.; Guerrini, R.; Donati, M. A.; Morrone, A..
J INHERIT METAB DIS. 2008. ; 31(0):447P -

52. Clinical phenotype of Italian patients with Hunter syndrome: Data from HOS - The Hunter Outcome Survey.
Parini, R.; Melzi, M. L.; Rigoldi, M.; Sala, S.; Rampazzo, A.; Gabrielli, O.; DiRocco, M.; Feliciani, C.; Castorina, M.; Cicognani, A.; Scarpa, M..
J INHERIT METAB DIS. 2008. ; 31(0):456P -

53. Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: Final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase.
Harmatz, Paul; Giugliani, Roberto; Schwartz, Ida Vanessa D.; Guffon, Nathalie; Teles, Elisa Leao; Miranda, M. Clara Sa; Wraith, J. Edmond; Beck, Michael; Arash, Laila; Scarpa, Maurizio; Ketteridge, David; Hopwood, John J.; Plecko, Barbara; Steiner, Robert; Whitley, Chester B.; Kaplan, Paige; Yu, Zi-Fan; Swiedler, Stuart J.; Decker, Celeste.
MOL GENET METAB. 2008. ; 94(4):469-475

54. Lysosomal storage diseases and the blood-brain barrier.
Begley, DJ.; Pontikis, Charles C.; Scarpa, Maurizio.
Current Pharmaceutical Design. 2008. ; 14(16):1566-1580

55. Eighteen-year follow-up of the first Italian MPSI patient treated with bone marrow transplantation.
Messina, C.; Rampazzo, A.; Cesaro, S.; Monciotti, C.; Gasparotto, N.; Tomanin, R.; Scarpa, M..
Bone Marrow Transplantation. 2008. ; 41(10):905-906

56. Molecular markers for the follow-up of enzyme-replacement therapy in mucopolysaccharidosis type VI disease.
Di Natale, Paola; Villani, Guglielmo R. D.; Parini, Rossella; Scarpa, Maurizio; Parenti, Giancarlo; Pontarelli, Gianfranco; Grosso, Michela; Sersale, Giovanna; Tomanin, Rosella; Sibilio, Michelina; Barone, Rita; Fiumara, Agata.
BIOTECHNOL APPL BIOC. 2008. ; 49(0):219-223

57. Seventh international symposium on lysosomal storage diseases.
Aerts, Johannes; Beck, Michael; Martin, Rick; Scarpa, Maurizio.
ACTA PAEDIATR. 2008. ; 97(0):1-2

58. Lysosomal storage diseases: new challenges.
Scarpa, Maurizio; Eto, Yoshikatsu.
ACTA PAEDIATR. 2008. ; 97(0):5-6

59. Mucopolysaccharidosis type II in a female patient: clinical presentation and follow-up examination after 6 months of enzyme replacement therapy.
Rampazzo, A.; Cananzi, M.; Salviati, L.; Tomanin, R.; Gasparotto, N.; Drigo, P.; Scarpa, M..
ACTA PAEDIATR. 2008. ; 97(0):99-99

60. Efficient transduction of human amniotic stem cells with an adenovirus-expressing iduronate-2-sulphatase: a potential approach for therapy of mucopolysaccharidosis type II?.
Grisafi, D.; Friso, A.; Piccoli, M.; Pozzobon, M.; De Coppi, P.; Chiandetti, L.; Zaramellal, P.; Scarpa, M.; Tomanin, R..
ACTA PAEDIATR. 2008. ; 97(0):102-102

61. Efficacy of adenovirus-mediated gene therapy in the mouse model of mucopolysaccharidosis type II.
Tomanin, R.; Zaccariotto, E.; Marigo, I.; Friso, A.; Grisafi, D.; Bordin, M.; Salvalaio, M.; Scarpa, M..
ACTA PAEDIATR. 2008. ; 97(0):102-

62. Neurological manifestations of Hunter syndrome: new insights from HOS - the Hunter outcome survey.
Scarpa, M.; Beck, M.; Wraith, J. E..
ACTA PAEDIATR. 2008. ; 97(0):103-104

63. A rapid testing procedure for Fabry disease: alpha-galadosidase A assay in dried blood spots.
Gasparotto, N.; Tomanin, R.; Frigo, A. C.; Pasquini, E.; Donati, A.; Niizawa, G.; Blanco, M.; Scarpa, M..
ACTA PAEDIATR. 2008. ; 97(0):112-

64. Neurological examinations and clinical manifestations in MPS I Registry patients.
Scarpa, Maurizio.
MOL GENET METAB. 2008. ; 93(2):81 -

65. Brains for brain: A new Consortium for the research and the therapy of LSDs.
Scarpa, Maurizio; Begley, David.
MOL GENET METAB. 2008. ; 93(2):82 -

66. In vivo evaluation of genistein for GAG storage reduction.
Scarpa, Maurizio; Friso, Adlelaide; Tomanin, Rosella; Salvalaio, Marika; Bordin, Mauro; Zacchello, Franco.
MOL GENET METAB. 2008. ; 93(2):83

67. Neurological manifestations of hunter syndrome: Insights from HOS, the hunter outcome survey.
Scarpa, Maurizio; Beck, Michael; Wraith, Edward J..
MOL GENET METAB. 2008. ; 93(2):84 -

68. A zebrafish iduronate-2-sulfatase candidate orthologue is strongly expressed during early embryonic development.
Scarpa, Maurizio; Moro, Enrico; Tomanin, Rosella; Friso, Adelaide; Modena, Nicola; Bortolussi, Marino; Argenton, Francesco.
MOL GENET METAB. 2008. ; 93(2):85 -

69. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy.
Wraith, J. Edmond; Scarpa, Maurizio; Beck, Michael; Bodamer, Olaf A.; De Meirleir, Linda; Guffon, Nathalie; Lund, Allan Meldgaard; Malm, Gunilla; Van der Ploeg, Ans T.; Zeman, Jiri.
EUR J PEDIATR. 2008. ; 167(3):267-277

70. Multidisciplinary Management of Hunter Syndrome.
Muenzer, Joseph; Beck, M.; Eng, C. M.; Escolar, M. L.; Giugliani, R.; Guffon, N. H.; Harmatz, P.; Kamin, W.; Kampmann, C.; Koseoglu, S. T.; Link, B.; Martin, R. A.; Molter, D. W.; Munoz Rojas, M. V.; Ogilvie, J. W.; Parini, R.; Ramaswami, U.; Scarpa, M.; Schwartz, I. V.; Wood, R. E.; Wraith, E..
Pediatrics. 2009. ; 124(6):E1228-E1239

71. Segregation analysis in a family at risk for the Maroteaux-Lamy syndrome conclusively reveals c.1151G > A (p.S384N) as to be a polymorphism.
Zanetti, Alessandra; Ferraresi, Elena; Picci, Luigi; Filocamo, Mirella; Parini, Rossella; Rosano, Camillo; Tomanin, Rosella; Scarpa, Maurizio.
European Journal of Human Genetics. 2009. ; 17(9):1160-1164

72. Mucopolysaccharidosis VI: the Italian experience.
Scarpa, Maurizio; Barone, Rita; Fiumara, Agata; Astarita, Luca; Parenti, Giancarlo; Rampazzo, Angelica; Sala, Stefania; Sorge, Giovanni; Parini, Rossella.
EUR J PEDIATR. 2009. ; 168(10):1203-1206

73. The burden of surgery in Hunter Syndrome: data from the Hunter OUTCOME SURVEY.
Parini, R.; Furfan, F.; Wraith, J. E.; Scarpa, M.; Beck, M.; Muenzer, J.; Giugliani, R..
MOL GENET METAB. 2009. ; 98(1):440 -

74. Rapid diagnostic testing procedures for lysosomal storage disorders: alpha-glucosidase and beta-galactosidase assays on dried blood spots.
Gasparotto, Nicoletta; Tomanin, Rosella; Frigo, Anna Chiara; Niizawa, Gabriela; Pasquini, Elisabetta; Blanco, Mariana; Donati, Maria Alice; Keutzer, Joan; Zacchello, Franco; Scarpa, Maurizio.
Clinica Chimica Acta. 2009. ; 402(1):38-41

75. Novel therapies and future perspectives.
Scarpa, M.; Frustaci, A..
International Journal of Clinical Pharmacology and Therapeutics. 2009. ; 47(0):S109-S110

76. CNS imaging evaluation: toward the creation of a severity score.
Manara, R.; Mardari, R.; Rampazzo, A.; Scarpa, M..
International Journal of Clinical Pharmacology and Therapeutics. 2010. ; 48(0):S38-S39

77. Genistein reduces glycosaminoglycan levels in a mouse model of mucopolysaccharidosis type II.
Friso, A.; Tomanin, R.; Salvalaio, M.; Scarpa, M..
British Journal of Pharmacology. 2010. ; 159(5):1082-1091

78. Enzyme replacement therapy for mucopolysaccharidosis VI: evaluation of long-term pulmonary function in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase.
Harmatz, Paul; Yu, Zi-Fan; Giugliani, Roberto; Schwartz, Ida Vanessa D.; Guffon, Nathalie; Teles, Elisa Leao; Sa Miranda, M. Clara; Wraith, J. Edmond; Beck, Michael; Arash, Laila; Scarpa, Maurizio; Ketteridge, David; Hopwood, John J.; Plecko, Barbara; Steiner, Robert; Whitley, Chester B.; Kaplan, Paige; Swiedler, Stuart J.; Hardy, Karen; Berger, Kenneth I.; Decker, Celeste.
J INHERIT METAB DIS. 2010. ; 33(1):51-60

79. A novel functional role of iduronate-2-sulfatase in zebrafish early development.
Moro, Enrico; Tomanin, Rosella; Friso, Adelaide; Modena, Nicola; Tiso, Natascia; Scarpa, Maurizio; Argenton, Francesco.
Matrix Biology. 2010. ; 29(1):43-50

80. A 10-year large-scale cystic fibrosis carrier screening in the Italian population.
Picci, Luigi; Cameran, Marilena; Marangon, Oriana; Marzenta, Diana; Ferrari, Stefano; Frigo, Anna Chiara; Scarpa, Maurizio.
Journal of Cystic Fibrosis. 2010. ; 9(1):29-35

81. Pathophysiology of neuropathic lysosomal storage disorders.
Bellettato CM, Scarpa M. (2010) J Inherit Metab Dis. 2010 Apr 29.

82. Home treatment with intravenous enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II - data from the Hunter Outcome Survey.
Burton BK, Guffon N, Roberts J, van der Ploeg AT, Jones SA; Scarpa M. HOS investigators.
Mol Genet Metab. 2010 Oct-Nov;101(2-3):123-9.

83. Systemic therapies for mucopolysaccharidosis: ocular changes following haematopoietic stem cell transplantation or enzyme replacement therapy,
Gail Summers C., Teär Fahnehjelm K., Pitz S., Guffon N., Koseoglu ST., Harmatz P., Scarpa M. (2010) Clin. Exp. Ophthalmol.

84. Enzyme replacement therapy for Mucopoloysaccharidosis VI: Growth abd pubertal development In patients treated with recombinant N-Acetylgalactosamine 4-sulfatase.
Decker C., Yu Z-F., Giugliani R., Schwartz IVD., Guffin N., Teles ES., Sa Miranda MC., Wraith JE., Beck M., Arash L., Scarpa M., Ketteridge D., Hopwood JJ., Plecko B., Steiner R., Whitley CB., Kaplan P., Swiedler SJ., Conrad S., and Harmatz P,. (2010) J. Ped. Rehabil. Med. 3, 2, 89 100.

85. Evaluation of disease severity in mucopolysaccharidosis
Beck M., Muenzer J., and Scarpa M., (2010)
J. Pediat. Rehabil. Med. 3, 39-46

86. Diagnosis and Management of ophthalmologic features in patients with mucopolysaccharidosis
Ferrari S., Ponzin D, Ashworth JL, Teär Fahnehjelm K., Summers CG. Harmatz P. and Scarpa M. (2011) Brit. J. Ophtalmol.95:613-9

87. Analysis of glucocerebrosidase activity in dry blood spots using tandem mass spectrometry.
Legini E, Orsini JJ, Hung C, Martin M, Showers A, Scarpa M, Zhang XK, Keutzer J, Mühl A, Bodamer OA. Clin Chim Acta. 2011 Jan 30;412(3-4):343-6.

88. IDUA mutational profiling of a cohort of 102 European patients with mucopolysaccharidosis type I:identification and characterization of 35 novel α-L-iduronidase (IDUA) alleles.Bertola F, Filocamo M, Casati G, Mort M, Rosano C, Tylki-Szymanska A, Tüysüz B, Gabrielli,O,Grossi S, Scarpa M, Parenti G, Antuzzi D, Dalmau J, Rocco MD, Vici CD, Okur I, Rosell J,Rovelli A, Furlan F, Rigoldi M, Biondi A, Cooper DN, Parini R.
Hum Mutat. 2011 Mar 10.

89. Brain and spine MRI features of Hunter disease: frequency, natural evolution and response to therapy.
Manara R, Priante E, Grimaldi M, Santoro L, Astarita L, Barone R, Concolino D, Di Rocco M, Donati MA, Fecarotta S, Ficcadenti A, Fiumara A, Furlan F, Giovannini I, Lilliu F, Mardari R, Polonara G, Procopio E, Rampazzo A, Rossi A, Sanna G, Parini R, Scarpa M.
J Inherit Metab Dis. 2011 Jun;34(3):763-80. Epub 2011 Apr 5.

90. Encapsulated engineered myoblasts can cure Hurler syndrome: preclinical experiments in the mouse model.
Piller Puicher E, Tomanin R, Salvalaio M, Friso A, Hortelano G, Marin O, Scarpa M.
Gene Ther. 2011 Jun 30. : 10.1038/gt.2011.94.

91. Lysosomal storage diseases: diagnostic confirmation and management of presymptomatic individuals.
Wang RY, Bodamer OA, Watson MS, Wilcox WR; M. Scarpa ACMG Work Group on Diagnostic Confirmation of Lysosomal Storage Diseases.
Genet Med. 2011 May;13(5):457-84.

92. GM1 gangliosidosis and Morquio B disease: an update on genetic alterations and clinical findings.
Caciotti A, Garman SC, Rivera-Colón Y, Procopio E, Catarzi S, Ferri L, Guido C, Martelli P, Parini R, Antuzzi D, Battini R, Sibilio M, Simonati A, Fontana E, Salviati A, Akinci G, Cereda C, Dionisi-Vici C, Deodato F, d'Amico A, d'Azzo A, Bertini E, Filocamo M, Scarpa M, di Rocco M, Tifft CJ, Ciani F, Gasperini S, Pasquini E, Guerrini R, Donati MA, Morrone A.
Biochim Biophys Acta. 2011 Jul;1812(7):782-90.

93. Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and management.
Braunlin EA, Harmatz PR, Scarpa M, Furlanetto B, Kampmann C, Loehr JP, Ponder KP, Roberts WC, Rosenfeld HM, Giugliani R.J Inherit Metab Dis. 2011 Jul 9.

94. The role of enzyme replacement therapy in severe Hunter syndrome-an expert panel consensus.
Muenzer J, Bodamer O, Burton B, Clarke L, Frenking GS, Giugliani R, Jones S, Rojas MV, Scarpa M, Beck M, Harmatz P.
Eur J Pediatr. 2012 Jan;171(1):181-8. Epub 2011 Oct 29.

95. Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease.
Scarpa M, Almássy Z, Beck M, Bodamer O, Bruce IA, De Meirleir L, Guffon N, Guillén-Navarro E, Hensman P, Jones S, Kamin W, Kampmann C, Lampe C, Lavery CA, Teles EL, Link B, Lund AM, Malm G, Pitz S, Rothera M, Stewart C, Tylki-Szymańska A, van der Ploeg A, Walker R, Zeman J, Wraith JE; Hunter Syndrome Europena Expert Council.
Orphanet J Rare Dis. 2011 Nov 7;6:72.

96. Closed Meningo(encephalo)cele: A New Feature in Hunter Syndrome.
Manara R, Priante E, Grimaldi M, Santoro L, Polonara G, Parini R, Scarpa M; on behalf of the Italian MPS Neuroimaging Study Group.
AJNR Am J Neuroradiol. 2011 Dec 22.

97. Non-convulsive status epilepticus of frontal origin in mucopolysaccharidosis type II successfully treated with ethosuximide.
Bonanni P, Gubernale M, Martinez F, Randazzo G, Milantoni L, Martinuzzi A, Boniver C, Vecchi M, Scarpa M.
Dev Med Child Neurol. 2012 Mar 14.

98. Gene Therapy Approaches For Lysosomal Storage Disorders, A Good Model For The Treatment Of Mendelian Diseases.
Tomanin R, Zanetti A, Zaccariotto E, D'Avanzo F, Bellettato CM, Scarpa M.
Acta Paediatr. 2012 Mar 16.

99. Capturing phenotypic heterogeneity in MPS I: results of an international consensus procedure.
de Ru MH, Teunissen QG, van der Lee JH, Beck M, Bodamer OA, Clarke LA, Hollak CE, Lin SP, Munoz Rojas MV, Pastores GM, Raiman JA, Scarpa M, Treacy EP, Tylki-Szymanska A, Wraith E, Zeman J, Wijburg FA.
Orphanet J Rare Dis. 2012 Apr 23;7(1):22

100. Enzyme replacement therapy for mucopolysaccharidosis VI: long-term cardiac effects of galsulfase (Naglazyme(®)) therapy.

Braunlin E, Rosenfeld H, Kampmann C, Johnson J, Beck M, Giugliani R, Guffon N, Ketteridge D, Sá Miranda CM, Scarpa M, Schwartz IV, Leão Teles E, Wraith JE, Barrios P, Dias da Silva E, Kurio G, Richardson M, Gildengorin G, Hopwood JJ, Imperiale M, Schatz A, Decker C, Harmatz P; MPS VI Study Group.

J INHERIT METAB Dis. 2012 Jun 5.

101. The Role of Visual Electrophysiology in Mucopolysaccharidoses.
Suppiej A, Rampazzo A, Cappellari A, Traverso A, Tormene AP, Pinello L, **Scarpa M**.
J CHILD NEUROL. 2012 AUG 21.

102. Immunologic privilege in the central nervous system and the blood-brain barrier.
Muldoon LL, Alvarez JI, Begley DJ, Boado RJ, Del Zoppo GJ, Doolittle ND, Engelhardt B, Hallenbeck JM, Lonser RR, Ohlfest JR, Prat A,**Scarpa M**, Smeyne RJ, Drewes LR, Neuwelt EA.
J CEREB BLOOD FLOW METAB. 2013 JAN;33(1):13-21

103. Respiratory and sleep disorders in mucopolysaccharidosis.
Berger KI, Fagondes SC, Giugliani R, Hardy KA, Lee KS, McArdle C,**Scarpa M**, Tobin MJ, Ward SA, Rapoport DM.
J INHERIT METAB DIS. 2013 Mar;36(2):201-10.

104. Human amniotic fluid stem cells protect rat lungs exposed to moderate hyperoxia.
Grisafi D, Pozzobon M, Dedja A, Vanzo V, Tomanin R, Porzionato A, Macchi V, Salmaso R, **Scarpa M**, Cozzi E, Fassina A, Navaglia F, Maran C, Onisto M, Caenazzo L, De Coppi P, De Caro R, Chiandetti L, Zaramella P.
PEDIATR PULMONOL. 2013 Mar 26.

105. The effect of idursulfase on growth in patients with Hunter syndrome: data from the Hunter Outcome Survey (HOS).
Jones SA, Parini R, Harmatz P, Giugliani R, Fang J, Mendelsohn NJ; HOS Natural History Working Group on behalf of HOS Investigators.
MOL GENET METAB. 2013 May;109(1):41-8.

106. Development of a Scoring System to Evaluate the Severity of Craniocervical Spinal Cord Compression in Patients with Mucopolysaccharidosis IVA (Morquio A Syndrome).
Möllmann C, Lampe CG, Müller-Forell W, **Scarpa M**, Harmatz P, Schwarz M, Beck M, Lampe C.
JIMD REP. 2013 Apr 12

107. Mucopolysaccharidoses and other lysosomal storage diseases.
Lampe C, Bellettato CM, Karabul N, **Scarpa M**.
RHEUM DIS CLIN NORTH AM. 2013 May;39(2):431-55

108. The blood-brain barrier friend or foe?
Scarpa M, Begley D. J I
Innherit Metab Dis. 2013 May;36(3):435-6

109. Extension of the molecular analysis to the promoter region of the iduronate 2-sulfatase gene reveals genomic alterations in mucopolysaccharidosis type II patients with normal coding sequence.
Brusius-Facchin AC, Abrahão L, Schwartz IV, Lourenço CM, Santos ES, Zanetti A, Tomanin R, **Scarpa M**, Giugliani R, Leistner-Segal S.
GENE. 2013 May 21

110. Treatment of hip dysplasia in patients with mucopolysaccharidosis type I after hematopoietic stem cell transplantation: results of an international consensus procedure.
Langereis EJ, Borgo A, Crushell E, Harmatz PR, van Hasselt PM, Jones SA, Kelly PM, Lampe C, van der Lee JH, Odent T, Sakkers R, **Scarpa M**, Schafroth MU, Struijs PA, Valayannopoulos V, White KK, Wijburg FA.
ORPHANET J RARE DIS. 2013 Oct 3;8(1):155

111. Circadian transcriptome analysis in human fibroblasts from Hunter syndrome and impact of iduronate-2-sulfatase treatment.
Mazzoccoli G, Tomanin R, Mazza T, D Avanzo F, Salvalaio M, Rigon L, Zanetti A, Pazienza V, Francavilla M, Giuliani F, Vinciguerra M, **Scarpa M**.
BMC MED GENOMICS. 2013 Oct 2;6(1):37.

112. Chiari 1 Malformation and Holocord Syringomyelia in Hunter Syndrome.
Manara R, Concolino D, Rampazzo A, Zanetti A, Tomanin R, Faggin R, **Scarpa M**.
JIMD REP. 2013 Jul 2.

113. Murine neural stem cells model Hunter disease in vitro: glial cell-mediated neurodegeneration as a possible mechanism involved.
Fusar Poli E, Zalfa C, D'Avanzo F, Tomanin R, Carlessi L, Bossi M, Nodari LR, Binda E, Marmiroli P, **Scarpa M**, Delia D, Vescovi AL, De Filippis L.CELL DEATH DIS. 2013 Nov 7;4:

114. Molecular Analysis of Turkish Maroteaux-Lamy Patients and Identification of One Novel Mutation in the Arylsulfatase B (ARSB) Gene.

Zanetti A, Onenli-Mungan N, Elcioglu N, Ozbek MN, Kör D, Lenzini E, **Scarpa M**, Tomanin R.
JIMD Rep. 2013 Nov 16.

115. Mucopolysaccharidoses and other lysosomal storage diseases.
Lampe C, Bellettato CM, Karabul N, **Scarpa M**.
RHEUM DIS CLIN NORTH AM. 2013 May;39(2):431-55

116. Nocturnal frontal lobe epilepsy in mucopolysaccharidosis.
Bonanni P, Volzone A, Randazzo G, Antoniazzi L, Rampazzo A, **Scarpa M**, Nobili L.
BRAIN DEV. 2014 Jan 18.

117. A column-switching HPLC-MS/MS method for mucopolysaccharidosis type I analysis in a multiplex assay for the simultaneous newborn screening of six lysosomal storage disorders.
Gucciardi A, Legnini E, Di Gangi IM, Corbetta C, Tomanin R, **Scarpa M**, Giordano G.
BIOMED CHROMATOGR. 2014 Jan 22

118. Intratechal delivery of protein therapeutics to the brain: a critical reassessment
Calias P., Banks WA., Begley D., **Scarpa M.**, Dickson P.,
Pharmacol Ther. 2014 May 20 ahead publication

119. A Hunter Patient with a Severe Phenotype Reveals Two Large Deletions and Two Duplications Extending 1.2 Mb Distally to IDS Locus.
Zanetti A, Tomanin R, Rampazzo A, Rigon C, Gasparotto N, Cassina M, Clementi M, **Scarpa M.**
JIMD Rep. 2014 Jul 25

120. Clinical efficacy of Enzyme Replacement Therapy in paediatric Hunter patients, an independent study of 3.5 years.
Tomanin R, Zanetti A, D Avanzo F, Rampazzo A, Gasparotto N, Parini R, Pascarella A, Concolino D, Procopio E, Fiumara A, Borgo A, Frigo A, **Scarpa M.**
Orphanet J Rare Dis. 2014 Sep 18;9(1):129.

121. Optimizing the molecular diagnosis of GALNS: novel methods to define and characterize Morquio-A syndrome-associated mutations.
Caciotti A, Tonin R, Rigoldi M, Ferri L, Catarzi S, Cavicchi C, Procopio E, Donati MA, Ficcadenti A, Fiumara A, Barone R, Garavelli L, Rocco MD, Filocamo M, Antuzzi D, **Scarpa M**, Mooney SD, Li B, Skouma A, Bianca S, Concolino D, Casalone R, Monti E, Pantaleo M, Giglio S, Guerrini R, Parini R, Morrone A.
Hum Mutat. 2015 Mar;36(3):357-68

122. The biological clock and the molecular basis of lysosomal storage diseases.
Mazzoccoli G, Mazza T, Vinciguerra M, Castellana S, **Scarpa M.**
JIMD Rep. 2015;18:93-105

123. Prevalence of anti-adeno-associated virus serotype 8 neutralizing antibodies and arylsulfatase B cross-reactive immunologic material in mucopolysaccharidosis VI patient candidates for a gene therapy trial.
Ferla R, Claudiani P, Savarese M, Kozarsky K, Parini R, **Scarpa M**, Donati MA, Sorge G, Hopwood JJ, Parenti G, Fecarotta S, Nigro V, Sivri HS, Van Der Ploeg A, Andria G, Brunetti-Pierri N, Auricchio A.
Hum Gene Ther. 2015 Mar;26(3):145-52

124. Cystic fibrosis carrier screening effects on birth prevalence and newborn screening.
Castellani C, Picci L, Tridello G, Casati E, Tamanini A, Bartoloni L, **Scarpa M**, Assael BM.
Genet Med. 2015 Jun 18

125. Neuronopathic lysosomal storage disorders: Approaches to treat the central nervous system.
Scarpa M, Bellettato CM, Lampe C, Begley DJ.
Best Pract Res Clin Endocrinol Metab. 2015 Mar;29(2):159-71

126. A Phase 3 Trial of Sebelipase Alfa in Lysosomal Acid Lipase Deficiency.
Burton BK, Balwani M, Feillet F, Barić I, Burrow TA, Camarena Grande C, Coker M, Consuelo-Sánchez A, Deegan P, Di Rocco M, Enns GM, Erbe R, Ezgu F, Ficicioglu C, Furuya KN, Kane J, Laukaitis C, Mengel E, Neilan EG, Nightingale S, Peters H, **Scarpa M**, Schwab KO, Smolka V, Valayannopoulos V, Wood M, Goodman Z, Yang Y, Eckert S, Rojas-Caro S, Quinn AG.
N Engl J Med. 2015 Sep 10;373(11):1010-20

127. Review and evaluation of the methodological quality of the existing guidelines and recommendations for inherited neurometabolic disorders.
Cassis L, Cortès-Saladelafont E, Molero-Luis M, Yubero D, González MJ, Herrero AO, Fons C, Jou C, Sierra C, Castejon Ponce E, Ramos F, Armstrong J, O'Callaghan MM, Casado M, Montero R, Olivas SM, Artuch R, Barić I, Bartoloni F, Bellettatc CM, Bonifazi F, Ceci A, Cvitanović-Šojat L, Dali CI, D'Avanzo F, Fumic K, Giannuzzi V, Lampe C, **Scarpa M**, Garcia-Cazorla Á.
Orphanet J Rare Dis. 2015 Dec 30;10:164.

128. Targeted Polymeric Nanoparticles for Brain Delivery of High Molecular Weight Molecules in Lysosomal Storage Disorders.
Salvalaio M, Rigon L, Belletti D, D'Avanzo F, Pederzoli F, Ruozi B, Marin O, Vandelli MA, Forni F, **Scarpa M**, Tomanin R, Tos G.
PLoS One. 2016 May 26;11(5):e0156452. : 10.1371/journal.pone.0156452.

129. Glial degeneration with oxidative damage drives neuronal demise in MPSII disease.
Zalfa C, Verpelli C, D'Avanzo F, Tomanin R, Vicidomini C, Cajola L, Manara R, Sala C, **Scarpa M**, Vescovi AL, De Filippis L.
Cell Death Dis. 2016 Aug 11;7(8):e2331

130. The ethical framework for performing research with rare inherited neurometabolic disease patients.
Giannuzzi V, Devlieger H, Margari L, Odlind VL, Ragab L, Bellettato CM, D'Avanzo F, Lampe C, Cassis L, Cortès-Saladelafont E, Cazorla ÁG, Barić I, Cvitanović-Šojat L, Fumić K, Dali CI, Bartoloni F, Bonifazi F, **Scarpa M**, Ceci A.
Eur J Pediatr. 2017 Mar;176(3):395-405.

131. Ten years of the Hunter Outcome Survey (HOS): insights, achievements, and lessons learned from a global patient registry.
Muenzer J, Jones SA, Tylki-Szymańska A, Harmatz P, Mendelsohn NJ, Guffon N, Giugliani R, Burton BK, **Scarpa M**, Beck M, Jangelind Y, Hernberg-Stahl E, Larsen MP, Pulles T, Whiteman DAH.
Orphanet J Rare Dis. 2017 May 2;12(1):82. .

132. Lysosomal Storage Diseases: Challenges in Multiprofessional Patient Care with Enzyme Replacement Therapy.
Das AM, Lagler F, Beck M, **Scarpa M**, Lampe C.
Klin Padiatr. 2017 May 2. [Epub ahead of print] German

133. European Reference Networks : Consequences for healthcare in Germany.
Graessner H, Schäfer F, **Scarpa M**, Wagner TOF.
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2017 May;60(5):537-541 German.

134. The Complexity of Pain Management in Children Affected by Mucopolysaccharidoses.
Congedi S, Di Pede C, Scarpa M, Rampazzo A, Benini F.
Case Rep Pediatr. 2017;2017:7257230

135. Brain RNA-Seq Profiling of the Mucopolysaccharidosis Type II Mouse Model.
Salvalaio M, D'Avanzo F, Rigon L, Zanetti A, D'Angelo M, Valle G, Scarpa M, Tomanin R.
Int J Mol Sci. 2017 May 17;18(5).

136. Birth weight in patients with mucopolysaccharidosis type II: Data from the Hunter Outcome Survey (HOS).
Bodamer O, Scarpa M, Hung C, Pulles T, Giugliani R.
Mol Genet Metab Rep. 2017 May 3;11:62-64.

137. The treatment of juvenile/adult GM1-gangliosidosis with Miglustat may reverse disease progression.
Deodato F, Procopio E, Rampazzo A, Taurisano R, Donati MA, Dionisi-Vici C, Caciotti A, Morrone A, Scarpa M. Metab Brain Dis. 2017 Oct;32(5):1529-1536

138. Open issues in Mucopolysaccharidosis type I-Hurler.
Parini R, Deodato F, Di Rocco M, Lanino E, Locatelli F, Messina C, Rovelli A, Scarpa M.
Orphanet J Rare Dis. 2017 Jun 15;12(1):112.

139. Clinical outcomes in idursulfase-treated patients with mucopolysaccharidosis type II: 3-year data from the hunter outcome survey (HOS).
Muenzer J, Giugliani R, Scarpa M, Tylki-Szymańska A, Jego V, Beck M.
Orphanet J Rare Dis. 2017 Oct 3;12(1):161

140. Treatment of brain disease in the mucopolysaccharidoses.
Scarpa M, Orchard PJ, Schulz A, Dickson PI, Haskins ME, Escolar ML, Giugliani R.
Mol Genet Metab. 2017 Dec;122S:25-34.

141. Epilepsy in mucopolysaccharidosis disorders.
Scarpa M, Lourenço CM, Amartino H.
Mol Genet Metab. 2017 Dec;122S:55-61.

142. Inborn Errors of Metabolism Involving Complex Molecules: Lysosomal and Peroxisomal Storage Diseases.
Bellettato CM, Hubert L, Scarpa M, Wangler MF.
Pediatr Clin North Am. 2018 Apr;65(2):353-373.

143. Easy-to-use algorithm would provide faster diagnoses for mucopolysaccharidosis type I and enable patients to receive earlier treatment.
Tylki-Szymańska A, De Meirleir L, Di Rocco M, Fathalla WM, Guffon N, Lampe C, Lund AM, Parini R, Wijburg FA, Zeman J, Scarpa M. Acta Paediatr. 2018 Aug;107(8):1402-1408.

144. International working group identifies need for newborn screening for mucopolysaccharidosis type I but states that existing hurdles must be overcome.
Parini R, Broomfield A, Cleary MA, De Meirleir L, Di Rocco M, Fathalla WM, Guffon N, Lampe C, Lund AM, Scarpa M, Tylki-Szymańska A, Zeman J. Acta Paediatr. 2018 Dec;107(12):2059-2065.

145. Mucopolysaccharidosis Type II.
Scarpa M.
In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews®[Internet]. Seattle (WA): University of Washington, Seattle; 1993-2018.
2007 Nov 6 [updated 2018 Oct 4].

146. Possible strategies to cross the blood-brain barrier.
Bellettato CM, Scarpa M.
Ital J Pediatr. 2018 Nov 16;44(Suppl 2):131.

147. Molecular diagnosis of patients affected by mucopolysaccharidosis: a multicenter study.
Zanetti A, D'Avanzo F, Rigon L, Rampazzo A, Concolino D, Barone R, Volpi N, Santoro L, Lualdi S, Bertola F, Scarpa M, Tomanin R. Eur J Pediatr. 2019 May;178(5):739-753.

148. Targeting Brain Disease in MPSII: Preclinical Evaluation of IDS-Loaded PLGA Nanoparticles.
Rigon L, Salvalaio M, Pederzoli F, Legnini E, Duskey JT, D'Avanzo F, De Filippis C, Ruozi B, Marin O, Vandelli MA, Ottonelli I, Scarpa M, Tosi G, Tomanin R. Int J Mol Sci. 2019 Apr 24;20(8)

149. Recommendations for the management of MPS VI: systematic evidence- and consensus-based guidance.
Akyol MU, Alden TD, Amartino H, Ashworth J, Belani K, Berger KI, Borgo A, Braunlin E, Eto Y, Gold JI, Jester A, Jones SA, Karsli C, Mackenzie W, Marinho DR, McFadyen A, McGill J, Mitchell JJ, Muenzer J, Okuyama T, Orchard PJ, Stevens B, Thomas S, Walker R, Wynn R, Giugliani R, Harmatz P, Hendriksz C, Scarpa M; MPS Consensus Programme Steering Committee; MPS Consensus Programme Co-Chairs.
Orphanet J Rare Dis. 2019 May 29;14(1):118.

150. Recommendations for the management of MPS IVA: systematic evidence- and consensus-based guidance.
Akyol MU, Alden TD, Amartino H, Ashworth J, Belani K, Berger KI, Borgo A, Braunlin E, Eto Y, Gold JI, Jester A, Jones SA, Karsli C, Mackenzie W, Marinho DR, McFadyen A, McGill J, Mitchell JJ, Muenzer J, Okuyama T, Orchard PJ, Stevens B, Thomas S, Walker R, Wynn R, Giugliani R, Harmatz P, Hendriksz C, Scarpa M; MPS Consensus Programme Steering Committee; MPS Consensus Programme Co-Chairs.
Orphanet J Rare Dis. 2019 Jun 13;14(1):137

Date 28/6/22 Signature

I consent to the use of my personal data, in accordance with the current law (General Data protection Regulation GDPR Regulation EU 2016/679; Italian law no. 196/2003 on privacy)